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Abstract Isoprenoids are synthesised either through the classi-
cal, mevalonate pathway, or the alternative, non-mevalonate, 2-
C-methyl-D-erythritol 4-phosphate (MEP) pathway. The latter
is found in many microbial pathogens and proceeds via (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP), a po-
tent activator of human VQ9/VN2 T cells. Listeria monocyto-
genes is the only pathogenic bacterium known to contain both
pathways concurrently. Strategic gene knockouts demonstrate
that either pathway is functional but dispensable for viability.
Yet, disrupting the mevalonate pathway results in a complemen-
tary upregulation of the MEP pathway. VQ9/VN2 T cell bioac-
tivity is increased in vlytB mutants where HMB-PP accumula-
tion is expected, and lost in vgcpE mutants which fail to
produce HMB-PP.
. 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
In humans, QN T cells normally constitute 0.5^5% of periph-
eral blood T cells and comprise a number of subpopulations
characterised by the distinct repertoire of their antigen recep-
tors encoded by certain VQ and VN gene segments, the major-
ity of which express the VQ9/VN2 T cell receptor. Elevated
levels of VQ9/VN2 T cells in the peripheral blood of patients
are documented in a variety of microbial infections [1]. The
responsible VQ9/VN2 T cell-stimulating compound common to
the respective pathogens is likely to be identical to the highly
active non-peptidic compound, (E)-4-hydroxy-3-methyl-but-2-
enyl pyrophosphate (HMB-PP), initially isolated from Esche-
richia coli [2,3]. HMB-PP turned out to be the direct precursor
of isopentenyl pyrophosphate (IPP) within the non-mevalo-
nate, 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway
of isoprenoid biosynthesis. In this respect, the two recently
discovered enzymes HMB-PP synthase (GcpE) and HMB-
PP reductase (LytB) play a key role in HMB-PP metabolism
[4,5]. Homologues of the genes encoding the enzymes of the
MEP pathway, including gcpE and lytB, are found in patho-
genic organisms as diverse as Brucella, Francisella, Mycobac-
terium, Pseudomonas, Salmonella, and Plasmodium, and cor-
relate with their VQ9/VN2 T cell stimulatory capacity [6,7].
Bacterial species that lack the MEP pathway and synthesise
IPP via the classical mevalonate pathway instead, such as
Streptococcus, Staphylococcus and Borrelia, are unable to pro-
duce HMB-PP and consequently do not speci¢cally activate
lymphocytes through the VQ9/VN2 T cell receptor.
Listeriosis, an opportunistic food-borne infection that pri-
marily a¡ects pregnant women and immunologically compro-
mised individuals, is also associated with elevated VQ9/VN2 T
cell numbers [8]. The disease is characterised by septicaemia
and eventually leads to infection of the foetus and abortion in
pregnant women, or life-threatening meningitis in non-preg-
nant individuals. Mortality rates of common-source outbreaks
often approach 30% [9,10]. The causative agent of human
listeriosis, Listeria monocytogenes, is remarkably resistant to
hostile environmental conditions and can grow at refrigera-
tion temperatures and high salt concentrations [9]. This ability
to sense and adapt to sudden changes in its environment is
crucial for environmental growth and subsequent pathogene-
sis [11]. A number of genetic loci have been identi¢ed that
play a role in survival of L. monocytogenes under extreme
conditions experienced both during food production and
host infection [12^15]. In particular, the ability of the patho-
gen to resist bile salts in the gastrointestinal tract is likely to
be important for colonisation and pathogenesis in food-borne
listeriosis [16,17]. A recent analysis of loci involved in bile
tolerance resulted in the isolation of a bile-intolerant mutant
that carries a disruption in the promoter region of the lytB
gene suggesting a role for the MEP pathway of isoprenoid
biosynthesis in bile resistance [16].
Previously, we demonstrated that lytB de¢ciency leads to
signi¢cant HMB-PP accumulation and increased VQ9/VN2 T
cell-dependent immunogenicity in E. coli [18]. In the current
study we investigated the e¡ect of imbalanced isoprenoid bio-
synthesis in general, and lytB de¢ciency in particular, on the
potential of L. monocytogenes to stimulate VQ9/VN2 T cells, as
an alteration in the production of the highly potent metabolite
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HMB-PP may a¡ect the immune response during the course
of infection in vivo.
2. Materials and methods
2.1. Genetic manipulations
Restriction enzymes were obtained from Roche (Mannheim, Ger-
many). Polymerase chain reactions (PCRs) were carried out using a
Hybaid PCR express system (Middlesex, UK) and products were pu-
ri¢ed with the QiaexII gel extraction kit (Qiagen, Hilden, Germany).
Plasmids were isolated with the Qiagen QIAprep Spin Miniprep Kit.
2.2. Construction of pORI19 mutants
Individual mutants were reconstructed by gene disruption followed
by a single crossover event, as described by Law et al. [19] for Lacto-
coccus lactis and Begley et al. [20] for L. monocytogenes. Brie£y, in-
ternal fragments of genes were generated by PCR with appropriate
primers (forward and reverse), which were modi¢ed to contain restric-
tion sites (see Table 1). These products were digested and ligated into
similarly digested pORI19. The resulting plasmids were transformed
into E. coli EC101 and then into L. monocytogenes harbouring the
temperature-sensitive helper plasmid pVE6007. In each case, one
transformant was grown overnight at 30‡C in brain^heart infusion
(BHI) supplemented with 5 Wg/ml erythromycin, after which 10 Wl
was transferred to BHI broth pre-warmed to the non-permissive tem-
perature of 42‡C. Following overnight incubation aliquots were plated
onto BHI containing 5 Wg/ml erythromycin. This selected for chromo-
somal integration at the point of homology with PCR products. Site-
speci¢c plasmid insertions were con¢rmed by PCR analysis using
primers for the plasmid (M13F/R) and primers that bind outside
the gene regions ampli¢ed (int primers).
2.3. Sequence analysis
Genomic sequences from bacterial species, as well as the protein
sequences derived thereof, were retrieved from the databases provided
by the National Center for Biotechnology Information (http://
www.ncbi.nlm.nih.gov) and the Institute for Genomic Research
(http://www.tigr.org). Sequence homologies were calculated using
EMBOSS/stretcher software for global pairwise alignments (http://
bioweb.pasteur.fr), multiple alignments were performed using CLUS-
TAL W (http://www.ebi.ac.uk) and BOXSHADE (http://bioweb.pas-
teur.fr) software.
2.4. QN T cell stimulation assays
Bacteria were harvested from fresh liquid cultures at an optical
density (OD)600 of 0.8, and sonicated in 1/10 volume phosphate-bu¡-
ered saline, pH 7.4. Low molecular weight (LMW) fractions were
obtained using Centriprep 3 kDa ¢lters (Millipore, Eschborn, Ger-
many). Flow cytometrical analysis of human peripheral blood mono-
nuclear cells (PBMCs) was performed as described before [18,21].
LMW samples were tested at serial dilutions between 1:10 and
1:106. Cells were harvested after 6 days, and analysed on an Epics
XL £ow cytometer (Beckman Coulter, Krefeld, Germany), using
CD3-PC5 and VQ9-£uorescein isothiocyanate monoclonal antibodies.
Bioactivity of bacterial extracts was determined using a standard
curve of synthetic HMB-PP [3], and expressed as the stimulatory
capacity comparable to an equivalent concentration of HMB-PP.
3. Results and discussion
3.1. The L. monocytogenes genome contains the genes of both
pathways of isoprenoid biosynthesis
Of the bacterial genomes sequenced to date, the genomes of
L. monocytogenes and certain Streptomyces species appear
unique in containing the genes of both the classical mevalo-
nate and the alternative MEP pathways of isoprenoid biosyn-
thesis (Fig. 1, Table 2). In all other microorganisms examined
thus far these pathways are mutually exclusive [22,23]. The
presence of intact genes encoding enzymes from both path-
ways implies that L. monocytogenes may be capable of syn-
thesising the isoprenoid precursor IPP via either route. This
may increase the metabolic £exibility of L. monocytogenes rel-
ative to other bacterial species and ensure isoprenoid biosyn-
thesis under conditions that would normally block a single
pathway.
3.2. The presence of either pathway is dispensable for the
survival of L. monocytogenes mutants
In an attempt to understand the signi¢cance of both com-
plete pathways of isoprenoid biosynthesis in L. monocyto-
Table 1
PCR primers used in this study
Primer Sequence (5P^3P)a
lmo0010F AATCAAGAATTCGACTCGAA
lmo0010R ATCGCCTTCTAGATGTGTC
lmo0010int CTTAGCAGGAATCAAAGCA
lmo0825F ACTCGTCGACACCCAAGA
lmo0825R CGCCAATGGATCCCAAAC
lmo0825int ATGATTGGTCAGATTGAGTT
lmo1441F ACCCTACTGCAGACGGAA
lmo1441R CATTGCGGAATTCGAGGAA
lmo1441int GGTAACATTGGTCGCCGT
lmo1451F GCAAAAGCTTAACGACAATC
lmo1451R TTCGGGAATTCCCCCTTT
lmo1451int ATCCATTGGTATTTATACAGT
aNucleotides altered to contain restriction sites are underlined.
Fig. 1. Isoprenoid biosynthesis in L. monocytogenes via the classical
mevalonate pathway (left) and the alternative MEP pathway (right).
CDP-ME, 4-diphosphocytidyl-2-C-methyl-D-erythritol; CDP-MEP,
4-diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate; DMAPP,
dimethylallyl pyrophosphate; DOXP, 1-deoxy-D-xylulose 5-phos-
phate; MEcPP, 2-C-methyl-D-erythritol 2,4-cyclopyrophosphate; P,
phosphate.
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genes, insertion mutants were created in the genes encoding
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reduc-
tase (hmgr) and mevalonate kinase (mvk) for the mevalonate
pathway, and in the genes encoding HMB-PP synthase (gcpE)
and HMB-PP reductase (lytB) for the MEP pathway (Fig. 2).
Due to the large size of the inserted plasmid these disruptions
are likely to impact downstream genes in polycistronic sys-
tems in addition to the targeted determinant. This is partic-
ularly relevant for the disruption in mvk (lmo0010) which is
also likely to eliminate transcription of two further mevalo-
nate pathway genes, pmk (lmo0012) and mpd (lmo0011).
Mutants were created e⁄ciently and were stable (data not
shown). None of the mutants displayed any impaired growth
rates in BHI medium, showing that disrupting either pathway
can be fully complemented by the action of the other. This
con¢rms that L. monocytogenes is a convenient model system
(and the only pathogenic bacterial species known) for inves-
tigating both pathways of isoprenoid biosynthesis in the same
organism and under identical conditions. Previous mutation-
based studies on the MEP pathway in E. coli were only pos-
sible once a reconstructed heterologous operon was intro-
duced expressing three genes needed for the biosynthesis of
the essential metabolite IPP from exogenously provided me-
valonate [24]. This strategy did not allow for studies investi-
gating the interdependence and cross-regulation of both path-
ways as can now be achieved in L. monocytogenes or in
Streptomyces spp.
3.3. L. monocytogenes but not Listeria innocua drives
VQ9/VN2 T cell expansion in vitro
In contrast to L. monocytogenes, the closely related but
non-pathogenic species L. innocua possesses an incomplete
MEP pathway. Indeed, the L. innocua genome contains genes
encoding all enzymes of the MEP pathway with the exception
of gcpE and lytB (Table 2), suggesting that L. innocua is in-
capable of synthesising and metabolising HMB-PP, and that
isoprenoid biosynthesis in this species proceeds solely via the
mevalonate pathway. As gcpE de¢ciency in E. coli causes an
Table 2
Genes controlling isoprenoid biosynthesis in L. monocytogenes and L. innocua
Gene L. monocytogenesa L. innocuab % homology of L. monocytogenes proteins toc
cds no. cds no. L. innocua E. coli Streptococcus pyogenes
dxs 1 387 381^1 389 210 lmo1365 1 394 166^1396 064 lin1402 84.2 (89.0) 44.8 (61.1) ^
dxr 1 342 682^1 343 824 lmo1317 1 349 456^1 350 598 lin1354 95.8 (98.7) 41.1 (57.9) ^
ygbP 255 800^256 498 lmo0235 278 872^279 570 lin0267 85.3 (94.8) 35.7 (49.0) ^
ychB 193 989^194 870 lmo0190 225 918^226 793 lin0229 95.9 (98.6) 29.4 (48.2) ^
ygbB 256 491^256 964 lmo0236 279 563^280 036 lin0268 90.4 (96.2) 61.2 (72.5) ^
gcpE 1 474 802^1 475 908 lmo1441 ^ ^ ^ 47.8 (66.4) ^
lytB 1 483 549^1 484 544 lmo1451 ^ ^ ^ 33.7 (53.6) ^
atoB 1 443 873^1 445 042 lmo1414 1 451 921^1 453 090 lin1453 92.3 (97.4) 51.5 (67.5) 51.1 (69.9)
hmgs 1 445 192^1 446 358 lmo1415 1 453 240^1 454 406 lin1454 93.3 (96.9) ^ 49.7 (68.4)
hmgr 851 225^852 505 lmo0825 848 666^849 946 lin0821 88.5 (95.1) ^ 45.2 (58.9)
mvk 12 918^13 886 lmo0010 12 919^13 887 lin0010 96.3 (98.4) ^ 32.6 (49.5)
pmk 14 795^15 874 lmo0012 14 793^15 875 lin0012 98.9 (99.7) ^ 26.4 (46.1)
mpd 13 843^14 814 lmo0011 13 796^14 815 lin0011 92.3 (93.5) ^ 36.7 (58.5)
idi1? 395 602^396 111 lmo0368 169 535^170 044 lin0387 92.3 (95.9) 23.9 (39.1) ^
idi2 1 406 742^1 407 818 lmo1383 1 413 629^1 414 705 lin1420 91.1 (96.1) ^ 37.7 (58.4)
aCoding region and gene number in L. monocytogenes strain EGD-e genome (accession number NC_003210).
bCoding region and gene number in L. innocua strain Clip11262 genome (accession number NC_003212).
c% identity (similarity) of L. monocytogenes proteins with the corresponding homologues of L. innocua, E. coli, and S. pyogenes, as calculated
using the EMBOSS/stretcher software for global pairwise alignments.
Fig. 2. Genomic organisation of the genes encoding putative enzymes of the mevalonate and MEP pathways in L. monocytogenes. pORI: sites
of strategic knockout constructions.
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incapability to activate VQ9/VN2 T cells [25], we investigated
the natural immunogenicity of L. innocua in a model system
using human PBMCs. Indeed, whilst wild-type L. monocyto-
genes preparations were highly potent in stimulating expan-
sion of VQ9/VN2 T cells in vitro, L. innocua did not display any
signi¢cant QN T cell bioactivity above the background (data
not shown).
3.4. Impairment of lytB function increases the VQ9/VN2 T cell
bioactivity of L. monocytogenes
De¢ciency in lytB leads to signi¢cant HMB-PP accumula-
tion and increased VQ9/VN2 T cell bioactivity in E. coli [18].
Here, we tested whether the same holds true for L. monocy-
togenes despite the complementary presence of the mevalonate
pathway. Using a mutant with a disrupted lytB gene together
with the previously described bile-sensitive BSM5 mutant with
an insertion in the lytB promoter [16], we show that L. mono-
cytogenes with impaired lytB function has an increased QN T
cell bioactivity compared to the wild-type (Fig. 3). This e¡ect
was more pronounced when the lytB coding region was af-
fected by plasmid insertion, in contrast to the promoter mu-
tant in which transcription of the lytB gene may occur at a
reduced level. Thus, the results obtained with L. monocyto-
genes mirror the situation in E. coli, and although not for-
mally proven on the molecular level, the phenomenon is likely
to re£ect a similar accumulation of the LytB substrate, HMB-
PP.
3.5. The balance between the mevalonate and the MEP
pathways a¡ects the VQ9/VN2 T cell bioactivity of
L. monocytogenes
In order to obtain a greater insight into the contribution of
both pathways to the VQ9/VN2 T cell-dependent immunoge-
nicity, we subsequently compared all L. monocytogenes isopre-
noid biosynthesis mutants and calibrated their bioactivity
against a standard of synthetic HMB-PP (Fig. 4). While the
vlytB mutant showed a signi¢cant increase in QN T cell bio-
activity compared to the wild-type, the vgcpE mutant was
much less potent in stimulating VQ9/VN2 T cells than the
wild-type. The QN T cell bioactivity of the vgcpE mutant
was actually similar to the naturally gcpE- (and lytB-) de¢-
cient species L. innocua. Strikingly, de¢ciency in either mvk or
in hmgr led to an elevated QN T cell bioactivity compared to
the L. monocytogenes wild-type. This implies that a disruption
of the mevalonate pathway can be compensated by a higher
throughput via the alternative pathway in order to maintain a
su⁄cient supply of isoprenoid precursor molecules, judged by
increased concentrations of the intermediate HMB-PP. A ¢ne-
tuned cross-regulation between both pathways may also be
the reason for the rather modest accumulation of HMB-PP
by the lytB-de¢cient L. monocytogenes mutant when com-
pared to previous studies with lytB-de¢cient E. coli. In the
current study a 7-fold accumulation of HMB-PP occurs for
the L. monocytogenes vlytB mutant relative to the wild-type
whereas previous studies have demonstrated a 150-fold in-
crease in bioactivity in the E. coli model [18].
Fig. 3. Impairment of lytB function increases the QN T cell bioactiv-
ity of bacterial extracts. Serial dilutions of LMW preparations from
L. monocytogenes wild-type bacteria (¢lled circles), bile-sensitive L.
monocytogenes BSM5 mutants with disrupted lytB promoter (empty
circles), and lytB-de¢cient L. monocytogenes vlmo1451 mutants
(¢lled triangles) were added to PBMC cultures. Data shown for QN
T cell outgrowth are means and S.E.M. from two independently
tested blood donors.
Fig. 4. Quanti¢cation of QN T cell bioactivities of bacterial extracts.
Bioactivity is expressed as absolute equivalents in nM HMB-PP (A),
or as the relative change compared to the L. monocytogenes wild-
type (B). Data shown are means and S.E.M. from six independently
tested blood donors. lmo, L. monocytogenes wild-type; lin, L. inno-
cua wild-type; mvk, mevalonate kinase (lmo0010); hmgr, HMG-CoA
reductase (lmo0825) ; gcpE, HMB-PP synthase (lmo1441) ; lytB,
HMB-PP reductase (lmo1451). *P6 0.05, and **P6 0.002, as deter-
mined by two-tailed Student’s t-tests for paired data.
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3.6. Implications of the interplay between the two pathways of
isoprenoid biosynthesis
The above ¢ndings indicate that a blockade in one pathway
of isoprenoid biosynthesis in L. monocytogenes can be fully
complemented by the action of the other, when mutants are
grown in complex media. Whether this holds true though
under physiologic in vivo conditions during the course of
host colonisation and infection remains to be investigated.
Mutants in one pathway of isoprenoid biosynthesis should
be highly susceptible to speci¢c inhibitors of the remaining
pathway. The antibiotic fosmidomycin is a potent inhibitor
of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (Dxr)
[26], the second enzyme within the MEP pathway. However,
this antibiotic did not inhibit the growth of either wild-type or
mutant bacteria, when tested on agar plates and in liquid
cultures at concentrations of up to 500 WM (data not shown).
This ¢nding was rather unexpected as survival of Listeria
strains de¢cient in the mevalonate pathway (vhmgr or
vmvk) should only be due to successful by-passing of the
defect by a fully operative MEP pathway. Fosmidomycin is
active against a range of Gram-negative bacteria including E.
coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae ([27] ;
data not shown), as well as against malaria parasites [28].
However, it does not show any signi¢cant activity on Burkhol-
deria cepacia, Clostridium perfringens, Mycobacterium tuber-
culosis, Neisseria gonorrhoeae, and others ([27] ; data not
shown), despite the presence of the MEP pathway in all these
species [6]. It is possible that L. monocytogenes and other
fosmidomycin-resistant bacteria possess mechanisms to ex-
clude the antibiotic from the bacterial cytoplasm. In the ab-
sence of drug-dependent targeting of the MEP pathway, the
construction of conditional double knockout mutants may be
a more favourable approach in the future to provide formal
proof that isoprenoid biosynthesis via either of the two path-
ways is required for in vitro and in vivo survival.
Our results using isoprenoid biosynthesis mutants are likely
to have important implications for the pathogenesis and im-
munity in Listeria infections, as a¡ecting the ¢ne-tuned bal-
ance between the two pathways had profound consequences
for the immunogenicity of the respective strain. While ele-
vated levels of VQ9/VN2 T cells are observed in many micro-
bial infections including listeriosis, there is still a considerable
debate whether this lymphocyte population has a role in clear-
ance and protective immunity, or is rather involved in im-
mune evasion of the pathogen and the establishment of
chronic disease. Recent reports suggested that VQ9/VN2 T cells
are important mediators of resistance against extracellular
bacterial infections [29]. However, the rapid and strong reac-
tivity of VQ9/VN2 T cells appears rather ine¡ective against
certain other pathogens as many microbial species manage
to escape the immune response nonetheless and establish
chronic and debilitating infections, such as tuberculosis and
malaria [6]. The mutants constructed in the present study
provide a powerful tool to scrutinise the role of VQ9/VN2 T
cells in the infectious process by comparing HMB-PP-over-
producing and HMB-PP-de¢cient strains. This will have to
be done in a primate model as besides humans, the VQ9/VN2
T cell subset and its response to non-peptidic antigens have so
far only been observed in rhesus macaques (Macaca mulatta)
and night monkeys (Aotus nancymaae) [30,31]. Other animals
including rodents and cattle do not appear to have homo-
logues to the VQ9 and VN2 T cell chains and do not react
towards non-peptidic antigens (e.g. [32]). However, uncou-
pling Listeria pathogenicity from the VQ9/VN2 T cell reactivity
might eventually lead to a thorough understanding of the role
of VQ9/VN2 T cells in microbial infection and have a funda-
mental impact on the creation of e¡ective vaccine strains.
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